Emmaus Life Sciences, Inc. announced the recent promotion of Willis Lee, Peter Ludlum and Lan Tran. Willis Lee, MS, has been appointed Vice-Chairman of the company's Board of Directors. His significant efforts have resulted in approximately $7 million in funding for the company in recent years from Korea and other Asian countries.

He will continue to serve as the company's Chief Operating Officer. Lee has served with the Company since 2009. Peter Ludlum, CMA, MBA, currently Chief Financial Officer, has been appointed Co-President of the company.

Ludlum's work has helped strengthen the company's internal controls and investor relations. He will continue to serve as the company's CFO. Ludlum has served with the company since 2012.

Lan Tran, MPH, currently Chief Administrative Officer, has been appointed Co-President of the company. Tran has led the regulatory process for the company's projects, including its pharmaceutical grade L-glutamine treatment (PGLG) therapy for sickle cell anemia, and is the primary point of contact to the FDA. She will continue to serve as the company's Chief Administrative Officer.

Tran has served with the company since 2008.